New drug Shingrix leads shingles vaccine mkt

...power of effective new drugs

Shingrix leads in sales in 7 months of release... Strong preventive effect despite high price shows effect in the market

SkyZoster, which made the lead for the first time in Q4 last year lost its lead to Shingrix

GlaxoSmithKline's shingles vaccine 'Shingrix' took the lead in Korea’s market just 7 months after its release.

 

With its powerful shingles prevention effect, its sales surpassed that of its competitors.

 

SkYZoster, a homegrown vaccine, had taken the lead in the market for the first time at the end of last year but was overtaken by Shingrix in just 2 quarters.

 

According to the market research institution IQVIA on the 26th, the market for preventive vaccines for shingles was KRW 45.4 billion in 1H last year, which was a 123.3% increase from the KRW 20.4 billion in 1H last year.

 

The shingles vaccine market grew 147.0% YoY to record KRW 21.9 billion in Q1 this year, then again rose 124.1% to KRW 23.5 billion.

 

The shingles vaccine market, which had only been KRW 10.5 billion in Q4 last year, saw a more than twofold increase in a single quarter.

 

This abrupt market expansion is related to the introduction of the new vaccine Shingrix.

 

Shingrix, which started being vaccinated in December last year, showed off its presence by occupying 28.9% of the market with sales of 6 billion won in Q1 this year.

 

In Q2, the drug quickly rose to lead the shingles vaccine market with sales of KRW 11.1 billion.

 

Shingrix's share of the shingles vaccine market in Q2 reached 47.4%.

 

In other words, within 7 months of its launch, the vaccine has occupied about half of the entire market.

 

The greatest benefit of Shignrix is its strong shingles prevention effect.

 

In a Phase III clinical trial (ZOE-50) that was conducted on adults aged over 50 years of age, Shingrix showed a 97.2% efficacy compared to the non-vaccinated group at 3.2 years of follow-up, and in another Phase III clinical trial (ZOE-70) conducted on adults aged 70 years and above, Shingrix showed an 89.8% efficacy at 3.7 years of follow up.

 

This is superior to the 5% protection in adults aged over 50 years of age and 41% in adults aged 70 years and above demonstrated with the use of Zostavax.

 

The prevention rate of SKYZoster is also known to be similar to Zostavax.

 

Also, Shingrix’s safety profile was confirmed through 5 clinical trials that were conducted on immunocompromised patients aged 18 years and older.

 

Based on such evidence, patients who received autologous hematopoietic stem cell transplantation or those with solid cancer, blood cancer, or solid organ transplant patients who have an increased risk of shingles are also eligible to receive vaccination with Shingrix.

 

At the time of its release, Shingrix's significantly higher price than existing vaccines was pointed to as an obstacle to the vaccine’s early settlement into the market.

 

vaccines.

 

The price of Shingrix, which is administered two times in total, is set at around KRW 500,000 to 600,000.

 

This is more than twice as high as the existing vaccine, which costs KRW 150,000 to 200,000.

 

However, Shingrix rapidly increased its market share in the market thanks to its superior efficacy despite the high price.

 

Also, the sales support from 2 domestic pharmaceutical companies contributed to Shingrix’s rapid market penetration.

 

GSK started domestic sales of Shingrix in partnership with two companies, GC Biopharma and Kwangdong Pharmaceutical.

 

Although other existing shingles vaccines like SKYZoster and Zostavax also saw a sales increase from last year, their market share declined due to Shingrix.

 

SK Bioscience’s SKYZoster’s sales had risen 83.2% YoY to record KRW 16.7 billion in 1H this year.

 

SKYZoster led the shingles market in Q1 with sales of KRW 9.5 billion, which is a 151.5% YoY increase.

 

SKYZoster’s sales continued to rise in Q2 to record KRW 6.5 billion, a 31.1% YoY increase, it lost its lead to Shingrix at the time.

 

Sky Zoster is a live attenuated vaccine for the prevention of shingles that was developed by SK Bioscience with its proprietary technology.

 

The vaccine has proven its non-inferiority compared to its competitor (Zostavax) in adults aged 50 or older in 8 domestic clinical institutions.

 

In October 2017, SK Bioscience obtained approval for SKYZoster from the Ministry of Food and Drug Safety for 'preventing shingles in adults over the age of 50'.

 

Before its approval, MSD's Zostavax was the only vaccine on the market.

 

SKYZoster’s sales surpassed Zostavax for the first time since its release in Q4 year and took the lead.

 

It maintained the lead for two consecutive quarters until Q1 this year.

 

However, due to Shingrix's rapid rise, the vaccine lost its lead after 2 quarters.

 

Zostavax’s sales in 1H this year was KRW 11.9 billion, up 2.6% YoY.

 

Zostavax’s sales in Q1 this year rose by 18.9% YoY to reach KRW 6 billion but then fell 10.1% to KRW 5.8 billion in Q2.

 

Zostavax lost its lead to SKYZoster in Q4 last year and then fell to third place with the introduction of Shingrix.

 

Zostavax only occupied 24.8% of the market in Q2.